The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC)

Prostate

Volumn 67, Issue 4, 2007, Pages 439-446

  Roobol, M J ^a   Zappa, M ^b   Maattanen L ^c   Ciatto, S ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^c FINNISH CANCER REGISTRY   (Finland)

Author keywords

Multicenter; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CANCER SCREENING; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; FINLAND; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCREENING TEST; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY; EUROPE; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847358127     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20545     Document Type: Article

References (29)

1. Roobol MJ, Schröder FH (guest editors). European Randomized Study of Screening for Prostate Cancer: Rationale, structure and preliminary results 1994-2003. BJU Int 2003;92 (Suppl 2):1-122.
2. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(6 Suppl):273S-309S.
3. Han M, Gann PH, Catalona WJ. Prostate-specific antigen and screening for prostate cancer. Med Clin North Am 2004;88(2):245-265.
4. Blijenberg BG, Lilja H, Neels H, Stenman U-H. Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: Report of the PSA Committee. BJU Int 2003;92 (Suppl 2):66-70.
5. Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast Th.H. Detection of prostate cancer: A comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000;56(4):617-621.
6. Roobol MJ, Schröder FH, Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006;66(6):604-612.
7. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004;172(4 Pt 1):1297-1301.
8. Hayek OR, Noble CB, de la Taille A, Bagiella E, Benson MC. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies. Curr Opin Urol 1999;9(5):371-375.
9. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98(8):529-534.
10. Schröder FH, Raaijmakers R, Postma R, van der kwast TH, Roobol MJ. 4 year Prostate Specific Antigen progression and diagnosis of prostate cancer in the European randomised study of Screening for Prostate Cancer, section Rotterdam. J Urology 2005;174:489-494.
11. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 1993;20(4):665-670.
12. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002;59(6):889-893; discussion 893-894.
13. Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, Hakama M, Tammela TL, Stenman UH. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002;41(6):619-626; discussion 626-627.
14. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267(16):2215-2220.
15. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, Walsh PC. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52(12):3323-3328.
16. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-990.
17. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-878.
18. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in prescreened populations? Eur Urol 2006;49(3):460-465; discussion 465.
19. Potter SR, Carter HB. The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep 2000;1(1):15-19. Review.
20. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445-1451.
21. Erratum in: JAMA 1997;278(2):118.
22. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90(10):766-771.
23. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-1507.
24. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbesdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-2003.
25. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 2007;177(1):107-112.
26. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003;98(7):1417-1422.
27. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. J Urol 2000;163(4):1144-1148.
28. Djavan B, Remzi M, Zlotta AR, Seitz C, Wolfram R, Hruby S, Bursa B, Schulman CC, Marberger M. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech Urol 1999;5(2):71-76.
29. Remzi M, Fong YK, Dobrovits M, Anagnostou T, Seitz C, Waldert M, Harik M, Marihart S, Marberger M, Djavan B. The Vienna nomogram: Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005;174(4 Pt 1):1256-1260; discussion 1260-1261; author reply 1261.